VTRS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

VT

Mkt Cap

$21.43B

Volume

7.35M

Next Earnings

November 5th

Loading chart

VT

VTRSViatris Inc. Common Stock

VTRS

Pay with—

Available Balance0.00

VT

Mkt Cap

$20.93B

Volume

7.35M

Next Earnings

November 5th

Chart Financials Earnings News About Dividends Insider Filings

Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaOpus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% (RYZUMVI®) for treating presbyopia in adults, expanding its previous indication for pharmacologically-induced mydriasis. The approval was supported by positive Phase 3 VEGA-2 and VEGA-3 trial results and will trigger a milestone payment from commercial partner Viatris Inc. Presbyopia affects approximately 90% of U.S. adults over 45, and the drug offers a non-invasive treatment option.GlobeNewswire Inc. · Oct 16, 2026

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioViatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio.Zacks Investment Research · Oct 9, 2026

Why Pacira BioSciences Skyrocketed TodayPacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business.The Motley Fool · Oct 8, 2026

VTRS vs. AVTR: Which Stock Is the Better Value Option?A comparison of two Medical Services sector stocks, Viatris (VTRS) and Avantor (AVTR), both holding a Zacks Rank #2 (Buy) rating. Based on valuation metrics including forward P/E ratio (7.01 vs 19.51), PEG ratio (1.92 vs 11.93), and P/B ratio (1.44 vs 1.9), Viatris emerges as the superior value opportunity with a Value grade of A compared to Avantor's C grade.Zacks Investment Research · Oct 6, 2026

Should Value Investors Buy Viatris (VTRS) Stock?Viatris (VTRS) is presented as an attractive value investment opportunity, holding a Zacks Rank #2 (Buy) rating with an 'A' Value grade. The stock demonstrates undervaluation across multiple metrics including a P/B ratio of 0.75 (below industry average of 2.17), P/S ratio of 1.37 (below industry average of 1.54), and P/CF ratio of 5.21 (significantly below industry average of 11.92), suggesting solid cash flow and earnings outlook.Zacks Investment Research · Oct 6, 2026

Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with strong performance potential. The Zacks Rank #1 stocks have averaged +23.86% annual returns since 1988, more than double the S&P 500. The article highlights Viatris (VTRS) as a stock to watch with a #3 Hold rank and VGM Score of A, noting recent upward earnings estimate revisions and positive momentum.Zacks Investment Research · Oct 5, 2026

Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now?The WisdomTree U.S. MidCap Dividend ETF (DON) is a smart beta ETF offering exposure to mid-cap dividend-paying stocks with a 0.38% expense ratio and 2.41% dividend yield. With $3.77 billion in assets and 295 holdings, it has delivered 6.93% returns year-to-date with medium risk (beta 0.86). However, cheaper alternatives like Vanguard's VOE (0.05% expense ratio) and iShares' IWS (0.23% expense ratio) offer lower-cost options for similar market exposure.Zacks Investment Research · Oct 2, 2026

Why Viatris (VTRS) is a Top Value Stock for the Long-TermRecent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. Market attention is now focused on the upcoming Friday employment report. Viatris (VTRS) is highlighted as a stock to watch with a Hold rating and attractive valuation metrics.Zacks Investment Research · Oct 1, 2026

Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and ViatrisThe generic drug industry shows mixed but resilient performance with companies focusing on operational efficiency and portfolio optimization. Three standout stocks—Amphastar Pharmaceuticals, Sandoz, and Viatris—are well-positioned to capitalize on industry evolution through new product launches, biosimilar expansion, and complex generics development. However, the industry faces persistent pricing pressure and competition, with the Zacks Medical-Generic Drugs industry ranked #160 out of 247 industries.Zacks Investment Research · Aug 31, 2026

3 Generic Drug Stocks to Watch Amid Improving Industry TrendsThe generic drug industry is experiencing a mixed but resilient operating environment with pricing pressures offset by healthy underlying demand and new product launches. Three companies—Amphastar Pharmaceuticals, Sandoz, and Viatris—are well-positioned to capitalize on industry evolution through biosimilar expansion, complex generics development, and operational efficiency improvements. The industry currently trades at a valuation discount compared to broader market indices.Zacks Investment Research · Aug 27, 2026

to start trading

VT

VTRSViatris Inc. Common Stock

VTRS

Pay with—

Available Balance0.00

Your PositionYou don't own any VTRS yet.

Related Tickers

Earnings

Dividends

Last · Aug 21Quarterly

Amount$0.12

Yield2.57%

Annual$0.48